SIGLEC9 and cervical carcinoma: To elucidate the interaction of SIGLEC9 with T-cell and MUC1, firstly, the authors used IHC and IF to verify MUC1 in patients with cervical cancer, and cells were upregulated (Fig. 7A‒B).